scholarly journals Cost analysis study of oral hypoglycemic agents available in Nepalese market

2015 ◽  
Vol 13 (2) ◽  
pp. 6-9
Author(s):  
Binaya Shrestha
Keyword(s):  
Economic Consequences ◽  
Hypoglycemic Agents ◽  
Pharmaceutical Companies ◽  
Manufacturing Companies ◽  
Oral Hypoglycemic Agents ◽  
Price Variation ◽  
Average Percentage ◽  
Wide Range ◽  
The Difference ◽  
Oral Hypoglycemic Drugs

Introduction: Diabetes Mellitus is one of the major causes of morbidity, mortality and needs lifelong treatment. There is a wide range of variation in the prices of antidiabetic drugs marketed in Nepal. Thus, a study was planned to find out price variations in the oral hypoglycemic drugs available singly and number of manufacturing companies for each, also to evaluate the difference in cost of different brands of same active drug by calculating percentage variation of cost.Methods: Cost of a particular drug being manufactured by different companies, in the same strength and dosage forms was obtained from the price list provided by the pharmaceutical companies in Nepal and Indian Drug Review September 2013. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in price was calculated.Results: Percentage price variation of the commonly used drugs found was metformin (500mg) 171.42%, metformin (850mg) 128.42%, metformin (1000mg) 80%, pioglitazone (15mg) 150% pioglitazone (30mg) 188.89%, sitagliptin (50mg) 33.33%, sitagliptin (100mg) 40% acarbose (25mg) 39.58%, acarbose (50mg) 32.60%, gliclazide (80mg) 108%, gliclazide (40mg) 83.33%, glibenclamide (2.5mg) 87%, glibenclamide (5mg), 80%, glimiperide (1mg) 91.67%, glimiperide (2mg) 300%, glimiperide (3mg) 100%, glimiperide (4mg) 36.84%.Conclusion: The average percentage price variation of different brands of the same oral hypoglycemic drugs manufactured in Nepal is very wide. The appraisal and management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences.

scholarly journals Cost variation analysis of oral anti-diabetic drugs

2018 ◽  
Vol 7 (9) ◽  
pp. 1709
Author(s):  
Rekha Mehani ◽  
Parag Sharma
Keyword(s):  
Diabetes Mellitus ◽  
Economic Consequences ◽  
Pharmaceutical Companies ◽  
Average Percentage ◽  
Cost Variation ◽  
Glucosidase Inhibitors ◽  
Large Numbers ◽  
The Difference ◽  
The Individual ◽  
Medical Specialities

Background: Diabetes Mellitus is a chronic metabolic disorder, one of the major causes of morbidity, mortality and needs lifelong treatment. There are large numbers of oral anti-diabetic drugs available for the treatment of type 2 diabetes mellitus. There are numerous brands available for each of the individual oral anti-diabetic drug. Thus, a study was planned to find out cost variation among different brands of same active oral anti-diabetic drug.Methods: Cost of a particular drug being manufactured by different companies, in the same strength and dosage forms was obtained from the price list provided by the pharmaceutical companies in Current Index of Medical Specialities (CIMS) (October 2017- January 2018). The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in price was analyzed.Results: Percentage cost variation of the commonly used drugs found was seen highest with Sulfonylureas (Glimepiride - 562%) followed by Metformin (492%) which was followed by Pioglitazone (488%), DPP-4 inhibitor Teneligliptin (231%), α- glucosidase inhibitors (Voglibose 284%), Meglitinides (Repaglinide 0.5mg 154%) and lowest was seen with Repaglinide 2mg (15%).Conclusions: There is very wide cost variation among different brands of the same oral anti-diabetic drugs manufactured in India. The average percentage cost variation of different brands of the same oral anti diabetic drugs manufactured in India is very wide. The appraisal and management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences.

scholarly journals Disparity in cost of oral hypoglycemic agents available in Indian market

2019 ◽  
Vol 8 (12) ◽  
pp. 2631
Author(s):  
Dheeraj Kumar Singh ◽  
Mukesh Kumar ◽  
Soni .
Keyword(s):  
Communicable Disease ◽  
Health Sector ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents ◽  
Price Variation ◽  
Medical Specialties ◽  
Sodium Glucose Cotransporter ◽  
Maximum Price ◽  
The Right ◽  
The Cost

Background: Diabetes is one of the most common non-communicable disease worldwide, of which India has been crowned with the title of “diabetes capital of the world”. On an average a person spends 20% of his or her income for the treatment of diabetes per year. So, it’s become very important to conduct a complete cost disparity study among oral hypoglycemic agent available in the market. Information generated from the current analysis, will be helpful to doctors in choosing the right drug for their patient and for the health sector in successfully utilizing the available resources.Methods: The study was conducted in the department of pharmacology AIIMS, Patna 2019. Price of the drugs per tablet/capsule/vial were reviewed from “Current Index of Medical Specialties” January-April 2019 and “Drug Today” October-December, 2018 for analysis of different formulations of oral hypoglycemic agents.Results: The cost of total 16 drugs belonging to 6 different classes, available in 38 different formulations were analyzed. Total 44 different pharmaceutical companies were involved in the manufacture of oral hypoglycemic agents. Overall glibenclamide (5 mg) and bromocriptine (2.5 mg) showed maximum % price variation of 422.79 and 586.27 respectively. Dapagliflozin and canagliflozin both belonging to sodium glucose cotransporter-2 inhibitors shows minimum price variation of 9.86 and 0.9 respectively.Conclusions: The current study shows that there is a huge price variation among oral hypoglycemic agents manufactured by different companies and government needs to take essential steps to bring about the uniformity in the price.

scholarly journals Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs

2019 ◽  
Vol 1 (2) ◽  
pp. 273-289 ◽  
Author(s):  
Junichi Kato ◽  
Yohei Shirakami ◽  
Masahito Shimizu
Keyword(s):  
Diabetes Mellitus ◽  
Colorectal Cancer ◽  
Colon Carcinogenesis ◽  
Basic Research ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents ◽  
Antitumor Effects ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Oral Hypoglycemic Drugs

The global deaths due to colorectal cancer and diabetes mellitus have increased by 57% and 90%, respectively. The relationship between various cancers and diabetes mellitus has been shown in multiple epidemiological studies. Hence, better management of diabetes mellitus is expected to reduce the risk of various cancers. This review focuses on colorectal cancer and aims to summarize recent findings on the antitumor effects of various oral hypoglycemic drugs on colorectal cancer and their estimated mechanisms. Of the seven classes of oral hypoglycemic agents, only metformin was found to have suppressive effects on colorectal cancer in both clinical and basic research. Clinical and basic researches on suppressing effects of glinides, dipeptidyl peptidase-4 inhibitors, thiazolidinedione, α-glucosidase inhibitors, and sodium glucose cotransporter-2 inhibitors against colon carcinogenesis have been insufficient and have not arrived at any conclusion. Therefore, further research regarding these agents is warranted. In addition, the suppressive effects of these agents in healthy subjects without diabetes should also be investigated.

scholarly journals Cost analysis of antipsychotic drugs available in India

2017 ◽  
Vol 6 (3) ◽  
pp. 669
Author(s):  
Ajay Kumar Shukla ◽  
Astha Agnihotri
Keyword(s):  
Antipsychotic Drug ◽  
Antipsychotic Drugs ◽  
Cost Ratio ◽  
Indian Market ◽  
Price Variation ◽  
Average Percentage ◽  
Cost Variation ◽  
Wide Range ◽  
The Government ◽  
The Cost

Background: Indian drug market has large numbers of branded formulations for every drug molecule. 1 Cost-sensitive healthcare environment has created a challenging workplace for clinicians. Efficient use of healthcare resources without compromising quality of patient care has been a challenging task for healthcare professionals. There is a wide range of variation in the prices of drugs marketed in India. Thus, a study was planned to analyse out cost variations of antiepileptic drugs available in Indian market.Methods: Minimum and maximum costs in Rupees (INR) of different brands of same generic antipsychotic drugs, in the same strength and dosage forms were compared. The cost ratio and percentage cost variation were calculated for each generic antipsychotic drug. The number of formulations for antipsychotic drugs and number of brands for each of them were also taken into consideration.Results: This study shows that in Indian market, there are wide variations in the prices of different brands of same generic antipsychotic drug. The highest cost ratio and percent cost variation was found for risperidone 2 mg [(1:16.27) and 1527.48], followed by risperidone 4 mg [(1:16.25) and 1525.25], risperidone 3 mg [(1:15.67) and 1467.33], risperidone 1 mg [(1:14.86) and 1386.78], olanzapine 10 mg [(1:12.36) and 1136.84], and olanzapine 5 mg [(1:12.31) and 1130.76]. Highest number of brands of antipsychotic drug available in Indian market are for divalproex sodium 500mg(25) followed by olanzapine 15 mg(23), olanzapine 5 mg(23), olanzapine 2.5mg(14), and risperidone 1 mg (14). Highest numbers of formulations of antipsychotic drug available in Indian market are for olanzapine(06), quetiapine(05), haloperidol(05), and aripiprazole(05).Conclusions: In Indian market, the average percentage price variation of different brands of the same oral antipsychotic drugs is very wide. Treatment with antipsychotic drugs usually has a long course with treatment adherence being a crucial factor for successful treatment. Improved adherence to the drug treatment can be ensured by decreasing the cost of therapy. Decreased drug cost expenditure can be ensured by changes in the government policies and regulations, integrating pharmacoeconomics as part of medical education curriculum, and creating awareness among treating physicians for switching to cost effective therapy.

scholarly journals Cost variation analysis of oral anti-diabetic agents available in Indian market

2021 ◽  
Vol 10 (6) ◽  
pp. 694
Author(s):  
Sanjay Gedam ◽  
Namita Barmaiya
Keyword(s):  
Drug Therapy ◽  
Calculated Data ◽  
Economic Consequences ◽  
Pharmaceutical Companies ◽  
Oral Antidiabetic Drugs ◽  
Combination Drug ◽  
Price Variation ◽  
Cost Variation ◽  
Maximum Price ◽  
Medical Specialities

Background: The objective of this study was to analyze cost variations of oral antidiabetic drugs available in Indian market.Methods: An observational study was carried out using CIMS (current index of medical specialities), (July 2020 to October 2020) and 1 mg.com, where difference in the maximum and minimum price of a particular drug, manufactured by different pharmaceutical companies, in the same strength, number and dosage form was compared and the percentage variation in price was calculated. Data was analyzed using descriptive statistical analysis.Results: The minimum and maximum percentage price variation for different classes of drugs respectively is as follows- in single drug therapy, the price variation between a sulfonylurea group of drugs glibenclamide (5 mg) shows maximum price variation of 400%, while glipizide (2.5 mg) shows variation of 81.8%. In biguanides, thizolidinediones and DPP4 inhibitor groups of drugs, metformin (500 mg), pioglitazone (30 mg) and vildagliptin show maximum price variation of 334.78%, 307 % and 264.6% respectively. In α- glucosidases inhibitor group of drugs voglibose (0.2 mg) shows maximum price variation of 284%. In meglitinides group of drugs, nateglinide (60 mg) shows maximum price variation of 284.6 %. In combination drug therapy, glimepiride and metformin combination (2+500 mg SR) shows the maximum variation up to 352.8%.Conclusions: The percentage cost variation of different brands of the same drug manufactured in India is very wide and the reason behind marketing a drug should be directed towards maximizing the benefit of therapy and minimizing negative personal and economic consequences.

scholarly journals Cross Referencing 2D-LC Determination of Intact Gliptins in Urine

2020 ◽  
Vol 58 (10) ◽  
pp. 907-914
Author(s):  
Amal M Mohamad ◽  
Cenk A Andac ◽  
Sena Caglar Andac
Keyword(s):  
Urine Samples ◽  
Hypoglycemic Agents ◽  
Therapeutic Drug ◽  
Two Dimensional ◽  
Oral Hypoglycemic Agents ◽  
Online Spe ◽  
Dipeptidyl Peptidase 4 ◽  
Wide Range ◽  
Dipeptidyl Peptidase 4 Inhibitors

Abstract Dipeptidyl peptidase-4 inhibitors, so-called gliptins, constitute a fairly novel class of oral hypoglycemic agents. The development and validation of an automated online SPE-LC-UV method to determine intact sitagliptin, saxagliptin, vildagliptin and metformin simultaneously in human urine samples were performed. For the two-dimensional chromatographic separation, a Gemini C18 (250.0 × 4.6 mm i.d., 110 A0, 5.0 μ) analytical column and a gradient elution with 10.0 mM o-phosphoric acid and methanol and for the online SPE analysis of urine samples, a LiChrospher® ADS SPE-column (20.0 mm × 2.0 mm i.d., 25.0 μm) were used through the study. The fractionation, transfer, elution and separation of the spiked urine samples were achieved in just 9.57 min runtime with 12.0 mL of solvent consumption which was green and economical compared to other sample preparation methods. The calibration curves were determined to be linear in a wide range of 0.10–100.00 μg/mL with satisfactory regression coefficients. Method developed for two-dimensional determination of gliptins would be useful as a reference in therapeutic drug monitoring and screening for forensic medical cases which involve the abuse, unintentional or misuse of multiple gliptins in terms of its practical use, easy detection and reliable results.

scholarly journals Hypoglycemic activity of Kaidarya Patra Choorna (Murraya koenigii linn.) in Diabetes mellitus type 2 with OHA’s

2020 ◽  
Vol 8 (06) ◽  
Author(s):  
Suraj Rawate
Keyword(s):  
Diabetes Mellitus ◽  
Modern Medicine ◽  
Hypoglycemic Agents ◽  
Placebo Control ◽  
Oral Hypoglycemic Agents ◽  
Plant Materials ◽  
Number Of Patients ◽  
Diet And Exercise ◽  
Treatment Of Diabetes ◽  
Oral Hypoglycemic Drugs

Abstract: Globally and nationally the Diabetes mellitus with its complications become the most important contemporary and challenging health problem. It should be treated with diet and exercise, typically in conjunction with oral hypoglycemic drugs (OHD) and the complications are so critical and hazardous, and oral hypoglycemic agents and insulin which is used for the treatment of diabetes mellitus by the allopathic system of medicine have numerous side effects. In spite of available treatment number of patients is on rise. It is convincing that the herbal or mineral remedies stated in ayurveda used singly or in combination have potency in the treatment of madhumeha. However, our country is indeed rich in its vast variety of flora, throught variegated physical feature of the land, extending from mountains to the oceans. The practitioners of Indian system of medicine have been using the plant materials and are claiming success in treatment of madhumeha even today. Therefore, taking a lead it will be worthwhile to reappraise the commonly used plant remedies in the treatment of madhumeha, with an unbiased scientific spirit. In Ayurveda kaidarya is mentioned as parvata nimba. Nimba is the best drug used in Prameha. Edible variety of Nimba i.e curry leaves can be useful. Kaidarya is having katu, tikta, and kashaya rasa and sheeta veerya. It pacifies vitiated kapha and pitta. Kaidarya has been used traditionally since few years for treatment of prameha. Placebo control may not be ethical in the disease hence single arm study along with modern medicine is preffered. Keywords: Diabetes mellitus, kaidarya, Oral Hypoglycemic agents

scholarly journals Cost analysis and price variation of commonly used drugs in obstetrics and gynecology in Jhalawar district of Rajasthan, India

2018 ◽  
Vol 7 (8) ◽  
pp. 1537
Author(s):  
Anshul Jhanwar ◽  
Neelam Sharma
Keyword(s):  
Folic Acid ◽  
Cost Analysis ◽  
Cost Effective ◽  
Obstetrics And Gynecology ◽  
Cost Ratio ◽  
Pharmaceutical Companies ◽  
Price Variation ◽  
Average Percentage ◽  
Ferrous Salt ◽  
The Government

Background: Drugs used in obstetrics and gynecology are strong selling drugs in pharmaceutical market but they are the least studied drugs in terms of cost analysis and price variation.Methods: Cost of most commonly used Obstetrics and Gynecology drugs in Jhalwar district manufactured by different pharmaceutical companies, in the same strength and dosage forms was obtained from Drug Today (January-March 2018). The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in cost per 10 tablets/10 capsule/1 injection/1 protein packet/1 sachet were analysed.Results: In Obstetrics drugs, the highest cost ratio (1:9.5) and percentage price variation (848) was found for Ferrous Salt + Folic acid combination followed by Cefixime (1:4.3, 330), Nifedipine (1:3.7, 270), Folic acid (1:3.67, 266), Paracetamol. Amoxicillin was having least cost ratio (1:1.4) and percentage price variation (37). Maximum number of brand available for Ferrous Salt + Folic acid combination (41) followed by Paracetamol, Calcium Salt + Vitamin D3 combination. In Gynecological drugs, the highest cost ratio (1:35) and percentage price variation (3433) was found for Ethinylestradiol + Levonorgetral combination followed by Doxycycline (1:8.9, 793), Fluconazole. Metronidazole was having least cost ratio (1:1.3) and percentage price variation (27). Maximum number of brand available for Omeperazole (27) followed by Ethamsylate (22).Conclusions: This study shows that the average percentage price variation of different brands of the same drugs were very wide. Improved adherence to the drug treatment can be ensured by decreasing the cost of therapy, which can be done by changes in the government policies and regulations, integrating pharmacoeconomics as part of medical education curriculum, and creating awareness among treating physicians for switching to cost effective therapy.

scholarly journals Price Variation of Injectable Antibiotics Commonly used in Bharatpur, Chitwan

2021 ◽  
Vol 14 (2) ◽  
pp. 137-140
Author(s):  
Ajit Kumar Sah ◽  
Anish Giri ◽  
Anjan Palikhey ◽  
Roshan Kumar Chaurasiya ◽  
Phoolgen Sah ◽  
...  
Keyword(s):  
Observational Study ◽  
Economic Burden ◽  
Retail Price ◽  
High Dispersion ◽  
Pharmaceutical Companies ◽  
Price Ratio ◽  
Price Variation ◽  
Percentage Difference ◽  
Wide Range

Introduction: High dispersion in price of injectable antibiotics makes choice of drugs difficult for the patients and increase economic burden. Thus, objective of this study is to find outrange of price variation of injectable antibiotics commonly used in Bharatpur, Chitwan. Methods: Descriptive observational study of 30 commonly used injectable antibiotics available in medical stores of Bharatpur, Chitwan was done. Range in price variation of the study items of different pharmaceutical companies was calculated in terms of price percentage difference and price ratio by selecting the highest and lowest price. The effect of rise in number of companies for the same drugs over the prices was also studied subjectively based upon graph. Results: We found that the price percentage difference was greatest (204.82%) for Ceftriaxone 500 mg. The maximum retail price (MRP) of the most expensive brand for Ceftriaxone 500 mg was almost three-fold higher than the MRP of the least expensive brand. The growing number of companies also increased dispersion in the price of drugs. Conclusions: There is wide range of price variation of injectable antibiotic commonly used in the Bharatpur, Chitwan. Increasing number of companies in the market has further widened the range. Policy to regulate the price of injectable antibiotic is needed.

Comparative Effects of High-Tech Visual Scene Displays and Low-Tech Isolated Picture Symbols on Engagement From Students With Multiple Disabilities

2019 ◽  
Vol 50 (4) ◽  
pp. 693-702 ◽  
Author(s):  
Christine Holyfield ◽  
Sydney Brooks ◽  
Allison Schluterman
Keyword(s):  
Language Learning ◽  
Augmentative And Alternative Communication ◽  
Visual Analysis ◽  
Multiple Disabilities ◽  
Visual Scene ◽  
Future Research ◽  
High Tech ◽  
Single Subject ◽  
Wide Range ◽  
The Difference

Purpose Augmentative and alternative communication (AAC) is an intervention approach that can promote communication and language in children with multiple disabilities who are beginning communicators. While a wide range of AAC technologies are available, little is known about the comparative effects of specific technology options. Given that engagement can be low for beginning communicators with multiple disabilities, the current study provides initial information about the comparative effects of 2 AAC technology options—high-tech visual scene displays (VSDs) and low-tech isolated picture symbols—on engagement. Method Three elementary-age beginning communicators with multiple disabilities participated. The study used a single-subject, alternating treatment design with each technology serving as a condition. Participants interacted with their school speech-language pathologists using each of the 2 technologies across 5 sessions in a block randomized order. Results According to visual analysis and nonoverlap of all pairs calculations, all 3 participants demonstrated more engagement with the high-tech VSDs than the low-tech isolated picture symbols as measured by their seconds of gaze toward each technology option. Despite the difference in engagement observed, there was no clear difference across the 2 conditions in engagement toward the communication partner or use of the AAC. Conclusions Clinicians can consider measuring engagement when evaluating AAC technology options for children with multiple disabilities and should consider evaluating high-tech VSDs as 1 technology option for them. Future research must explore the extent to which differences in engagement to particular AAC technologies result in differences in communication and language learning over time as might be expected.

Sign in / Sign up

Export Citation Format

Share Document